Repligen vs Bio-Techne
Repligen (RGEN), health care, and Bio-Techne (TECH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Bio-Techne is worth $11.4B on the stock market and Repligen $10.4B: Bio-Techne is valued at 10% more. Repligen's operating margin in its latest fiscal year was 7.47% and Bio-Techne's 20.7%. Over the past year Repligen's share price has moved +6.35% and Bio-Techne's +25.2%.
Key facts
- Repligen market value
- $10.4B
- Bio-Techne market value
- $11.4B
- Bio-Techne P/E
- 66.6
- Repligen revenue
- $738.3MFY to 2025-12-31
- Bio-Techne revenue
- $1.2BFY to 2026-06-30
- Superinvestors holding both
- 2
Market values as of .
| Measure | Repligen | Bio-Techne |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-06-30 |
| Size | ||
| Market cap | $10.4Blower | $11.4Bhigher |
| Revenue | $738.3Mlower | $1.2Bhigher |
| Earnings | $48.9Mlower | $181.9Mhigher |
| Employees | 2,000lower | 3,000higher |
| Total assets | $2.9Bhigher | $2.6Blower |
| Valuation | ||
| P/E | — | 66.6 |
| P/S | 14.1higher | 9.4lower |
| P/B | 4.4lower | 5.3higher |
| Dividend yield | 0.00%lower | 0.33%higher |
| Profitability | ||
| Operating margin | 7.47%lower | 20.7%higher |
| Balance sheet | ||
| Net assets | $2.1Blower | $2.1Bhigher |
| Total liabilities | $843.6Mhigher | $478.5Mlower |
| Total debt | $542.2Mhigher | $200Mlower |
| Cash on hand | $566Mhigher | $264.7Mlower |
| Price change | ||
| Today | -0.24%lower | -0.23%higher |
| 1 year | +6.35%lower | +25.2%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (2)
- Lee Ainslie2.4% / 1.0%
- Wallace Weitz0.5% / 1.3%
Repligen only (4)
- Brandon Haley0.4%
- Chuck Royce (founder)0.3%
- Stanley Druckenmiller0.2%
- Ron Baron0.2%
Bio-Techne only (5)
- Sequoia Fund team3.9%
- Mairs & Power team0.8%
- Henry Ellenbogen0.3%
- Paul Tudor Jones0.3%
- Larry Robbins0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Repligen / Bio-Techne). Who owns RGEN · Who owns TECH
More on Repligen
Further comparisons
Repligen against its closest peers
Bio-Techne against its closest peers
Learn
Questions and answers
Which is bigger, Repligen or Bio-Techne?
By market value, Bio-Techne is the larger: $11.4B against $10.4B for Repligen. By revenue in its latest fiscal year, Bio-Techne is the larger: $1.2B against $738.3M for Repligen.
Which has the higher operating margin?
Bio-Techne: 20.7%, against 7.47% for Repligen. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Bio-Techne: 0.33%, against 0.00% for Repligen. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Repligen: $542.2M, against $200M for Bio-Techne. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Repligen and Bio-Techne?
In their latest 13F filings, Lee Ainslie and Wallace Weitz hold both.
Cite this page
Funkfolio, “Repligen vs Bio-Techne”, data as of 17 November 2026. https://funkfolio.com/compare/rgen-vs-tech
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.